Robert W. Baird Trims Twist Bioscience (NASDAQ:TWST) Target Price to $33.00

Twist Bioscience (NASDAQ:TWSTGet Rating) had its price objective reduced by Robert W. Baird from $56.00 to $33.00 in a research report sent to investors on Monday morning, The Fly reports. They currently have an outperform rating on the stock.

A number of other equities analysts have also recently issued reports on the company. SVB Leerink decreased their target price on Twist Bioscience from $45.00 to $30.00 and set a market perform rating on the stock in a report on Monday. Barclays decreased their target price on Twist Bioscience from $45.00 to $43.00 and set an overweight rating on the stock in a report on Monday.

Twist Bioscience Stock Up 1.3 %

Shares of NASDAQ TWST opened at $25.53 on Monday. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -6.33 and a beta of 1.15. The stock’s fifty day simple moving average is $32.37 and its 200 day simple moving average is $36.79. Twist Bioscience has a 52-week low of $23.90 and a 52-week high of $99.74.

Insider Transactions at Twist Bioscience

In other news, SVP Paula Green sold 8,514 shares of the firm’s stock in a transaction on Friday, September 16th. The stock was sold at an average price of $37.43, for a total value of $318,679.02. Following the completion of the sale, the senior vice president now owns 14,199 shares of the company’s stock, valued at $531,468.57. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 9,211 shares of company stock valued at $341,371 over the last quarter. Company insiders own 3.10% of the company’s stock.

Institutional Trading of Twist Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of the business. Capital Impact Advisors LLC boosted its position in shares of Twist Bioscience by 6.3% in the third quarter. Capital Impact Advisors LLC now owns 19,177 shares of the company’s stock worth $487,000 after buying an additional 1,132 shares during the period. Sandia Investment Management LP acquired a new stake in Twist Bioscience during the third quarter valued at $88,000. BNP Paribas Arbitrage SNC boosted its position in Twist Bioscience by 593.0% during the third quarter. BNP Paribas Arbitrage SNC now owns 89,246 shares of the company’s stock valued at $3,145,000 after purchasing an additional 76,367 shares during the last quarter. Thrivent Financial for Lutherans acquired a new stake in Twist Bioscience during the third quarter valued at $1,978,000. Finally, Two Sigma Investments LP acquired a new stake in Twist Bioscience during the third quarter valued at $2,995,000.

About Twist Bioscience

(Get Rating)

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Articles

The Fly logo

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.